Ilaria D. G.
- Country
- Italy
- Department
- Hematology
Research Overview
- Phase II Evaluation of Tislelizumab Efficacy and Safety in De Novo Hodgkin Lymphoma Patients Ineligible for Standard Chemotherapy
- An open-label, randomized phase III trial comparing local radiotherapy alone or combined with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial from the Fondazione Italiana Linfomi
- Phase II Evaluation of Ibrutinib and Rituximab in Treatment-Naïve CD20-Positive Marginal Zone B-Cell Lymphoma Patients Requiring Systemic Therapy
Data & Insights
Has run more than one trial at 72 of 175 partner sites.
Specializations
Lymphoma Research Focus
This investigator specializes in treating various forms of lymphoma, with particular emphasis on Hodgkin's lymphoma and follicular lymphoma. Their research encompasses both early-stage and advanced disease states, exploring innovative therapeutic approaches.
- Advanced Treatment Strategies for Hodgkin's Lymphoma
- Early-Stage Follicular Lymphoma Management
- Marginal Zone B-cell Lymphoma Therapeutics
- Non-Hodgkin Lymphoma Interventions
Immunotherapy Applications
The investigator focuses on developing immunotherapy-based treatments for lymphoid malignancies, incorporating novel therapeutic agents and combinations to enhance treatment outcomes.
- Rituximab-Based Combination Therapies
- PD-1 Inhibitor Applications
- Targeted Immunotherapy Approaches
- Maintenance Treatment Strategies
Novel Therapeutic Approaches
Research interests include investigating innovative treatment combinations and exploring alternatives to conventional chemotherapy, particularly in treating rare and resistant forms of lymphoma.
- Chemotherapy-Free Alternatives
- BTK Inhibitor Therapies
- Combined Modality Treatments
- Radiotherapy Integration Strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.